EP
DNLI icon

Elkfork Partners’s Denali Therapeutics DNLI Stock Holding History

Elkfork Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$14K Hold
918
– – ﹤0.01% 1043
2019
Q2 		$19K Hold
918
– – ﹤0.01% 1033
2019
Q1 		$21K Hold
918
– – ﹤0.01% 1015
2018
Q4 		$19K Buy
+918
New +$16.7K ﹤0.01% 979

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Elkfork Partners's DNLI Position: Q3 2019 in Review

Elkfork Partners held its Denali Therapeutics (DNLI) position steady in Q3 2019 at 918 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #1043.

Elkfork Partners first reported a position in DNLI in Q4 2018 and has held it in 4 quarters since. The position peaked at $21K in Q1 2019. 118 funds tracked by Wall St. Rank hold DNLI as of Q3 2019.

  • Elkfork Partners held 918 shares of Denali Therapeutics worth $14K as of Q3 2019.
  • Elkfork Partners left its Denali Therapeutics share count unchanged in Q3 2019.
  • Denali Therapeutics made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #1043 holding.
  • Elkfork Partners first reported a position in Denali Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Elkfork Partners's Denali Therapeutics position peaked at $21K in Q1 2019.
  • 118 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.